BRAF(E600) in benign and malignant human tumours. – ScienceOpen
31
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      BRAF(E600) in benign and malignant human tumours.

      Oncogene
      Animals, Cell Proliferation, Humans, Neoplasms, metabolism, therapy, Proto-Oncogene Proteins B-raf, physiology, Signal Transduction

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Of the RAF family of protein kinases, BRAF is the only member to be frequently activated by mutation in cancer. A single amino acid substitution (V600E) accounts for the vast majority and results in constitutive activation of BRAF kinase function. Its expression is required to maintain the proliferative and oncogenic characteristics of BRAF(E600)-expressing human tumour cells. Although BRAF(E600) acts as an oncogene in the context of additional genetic lesions, in primary cells it appears to be associated rather with transient stimulation of proliferation. Eventually, BRAF(E600) signalling triggers cell cycle arrest with the hallmarks of cellular senescence, as is illustrated by several recent studies in cultured cells, animal models and benign human lesions. In this review, we will discuss recent advances in our understanding of the role of BRAF(E600) in benign and malignant human tumours and the implications for therapeutic intervention.

          Related collections

          Author and article information

          Journal
          17724477
          10.1038/sj.onc.1210704

          Chemistry
          Animals,Cell Proliferation,Humans,Neoplasms,metabolism,therapy,Proto-Oncogene Proteins B-raf,physiology,Signal Transduction

          Comments

          Comment on this article